Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(2.37)
# 1,207
Out of 4,667 analysts
40
Total ratings
42.42%
Success rate
-0.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Reiterates: Overweight | n/a | $72.67 | - | 6 | Jun 20, 2024 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.57 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $8.96 | - | 6 | Jun 20, 2024 | |
| BLTE Belite Bio | Reiterates: Overweight | n/a | $82.53 | - | 3 | Jun 20, 2024 | |
| ALLK Allakos | Reiterates: Neutral | n/a | $0.94 | - | 4 | Jun 20, 2024 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $0.84 | - | 3 | May 15, 2024 | |
| PSTX Poseida Therapeutics | Reiterates: Overweight | $14 | $2.72 | +414.71% | 2 | Oct 10, 2023 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $0.92 | +117.75% | 2 | Aug 31, 2023 | |
| CKPT Checkpoint Therapeutics | Maintains: Overweight | $19 → $14 | $3.38 | +314.20% | 4 | Aug 15, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $4.71 | +600.64% | 2 | Jul 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4.5 | $3.67 | +22.62% | 2 | May 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $220 → $100 | $1.49 | +6,611.41% | 2 | May 17, 2022 |
Insmed
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $72.67
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.57
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.96
Upside: -
Belite Bio
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $82.53
Upside: -
Allakos
Jun 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $0.94
Upside: -
Precigen
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.84
Upside: -
Poseida Therapeutics
Oct 10, 2023
Reiterates: Overweight
Price Target: $14
Current: $2.72
Upside: +414.71%
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $0.92
Upside: +117.75%
Checkpoint Therapeutics
Aug 15, 2023
Maintains: Overweight
Price Target: $19 → $14
Current: $3.38
Upside: +314.20%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $4.71
Upside: +600.64%
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $3.67
Upside: +22.62%
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $1.49
Upside: +6,611.41%